Highlights: Co-delivery of drugs-minicircle DNA by nanoparticle-in-microsphere multipart systems Gas-generating TPGS-PLGA microspheres present a pH-responsive.

Slides:



Advertisements
Similar presentations
Transfection The students need to have some background knowledge about recombinant DNA technology for this lecture. Key words: Transient transfection,
Advertisements

IIUM Research, Invention and Innovation Exhibition 2011 ‘ Enhancing Quality Research and Innovation for Societal Development’ Farahidah Mohamed, Ahmad.
IIUM Research, Invention and Innovation Exhibition 2011 ‘ Enhancing Quality Research and Innovation for Societal Development’ Farahidah Mohamed, Abd Almonem.
Improving solubility and cellular absorption of Paclitaxel with solid lipid nanoparticles and cyclodextrin Jong-Suep Baek, Jae-Woo So, Ji-Sook Hwang, Cheong-Weon.
Microbial Biotechnology Philadelphia University
Gene Therapy (III) “Non-Viral Gene Transfer Methods” Dr. Aws Alshamsan Department of Pharmaceutics Office: AA87 Tel:
NANOTECHNOLOGIES: THE NEW GENERATION OF MEDICINE Dr Mariano Licciardi.
Nanotechnology in Cancer Treatment
Nanodiamond Drug Delivery Austin Ramos Biomedical Engineering, URI BME 281.
Abstract Polymeric Porous microspheres are an effective drug delivery mechanism able to control drug release, preventing drug wastage and lowering costs.
Products > PC-3 Transfection Reagent (Prostate Cancer Cells) Altogen Biosystems offers the PC-3 Transfection Reagent among a host of 100+ cell line specific.
Dr Gillian Hutcheon Reader in Biomaterials School of Pharmacy and Biomolecular Sciences Liverpool John Moores University Polymeric nanoparticles for the.
Altogen labs Leading Developer and Manufacturer of In Vivo and DNA Transfection Kits, Transfection Reagents and Electroporation Delivery Products Products.
Altogen labs Leading Developer and Manufacturer of In Vivo and DNA Transfection Kits, Transfection Reagents and Electroporation Delivery Products Products.
Products > T98G Transfection Reagent (Glioblastoma Cells, CRL-1690)
Products > DI-TNC1 Transfection Reagent (Rat Brain Astrocytes)
Products > NCI-H1299 Transfection Reagent (Lung Adenocarcinoma)
Altogen labs Leading Developer and Manufacturer of In Vivo and DNA Transfection Kits, Transfection Reagents and Electroporation Delivery Products Products.
Hyaluronic acid-coated PEI-PLGA nanoparticles mediated co-delivery of doxorubicin and miR-542-3p for triple negative breast cancer therapy  Shengpeng.
Products > L6 Transfection Reagent (Myeloma Cells, CRL-1458)
Synthesis and Characterization of Cleavable Core-Crosslinked Micelles based on Amphiphilic Block Copolypeptoids towards Drug Delivery Applications Amphiphilic.
Iurii Antoniuk, Catherine Amiel  Journal of Pharmaceutical Sciences 
INCREASING CELL VIABILITY USING DOUBLE HYDROXIDE MATERIALS FOR BIOLOGICAL LABELING I.Castelló Serrano,1,* G. Stoica,2 E. Palomares2.
Products > DU145 Transfection Reagent (Prostate Carcinoma Cells)
Centre of Polymer Systems
Products > SK-MEL-28 Transfection Reagent (Melanoma Cells, HTB72)
Chitosan aqueous solution (0.1 mg/mL)
The effect of poloxamer 188 on nanoparticle morphology, size, cancer cell uptake, and cytotoxicity Nanomedicine: Nanotechnology, Biology, and Medicine.
Products > LoVo Transfection Reagent (Colon Adenocarcinoma)
Hybrid Nanomaterial Complexes for Advanced Phage-guided Gene Delivery
Products > AsPC-1 Transfection Reagent (Pancreatic Beta Cells)
Products > HUH-7 Transfection Reagent (Liver Cancer Cells)
Products > MDCK Transfection Reagent (Kidney Cells, CCL-34)
1. Thermoresposive Poly(N-alkylacrylamide) family, including Poly(N,N-diethylacrylamide) and Poly(N-isopropylacrylamide) display volume phase transitions.
Volume 24, Issue 7, Pages (July 2016)
Products > HCAEC Transfection Reagent (Coronary Artery Endothelial)
Products > A375 Transfection Reagent (Melanoma Cells, CRL-1619)
Preparation of magnetic drug-loaded PLGA nanospheres as biodegradable magneto-responsive drug carriers Mohsen Ashjari1, Sepideh Khoee *,2, Ali Reza Mahdavian.
Products > MEF Transfection Reagent (Mouse Fibroblast Cells)
Products > Hep-3B Transfection Reagent (Hepatocellular Carcinoma)
Particle assembly incorporating a VP22–BH3 fusion protein, facilitating intracellular delivery, regulated release, and apoptosis  N.D. Brewis, A. Phelan,
Dual Tumor-Targeting Nanocarrier System for siRNA Delivery Based on pRNA and Modified Chitosan  Lin Li, Xiaoqin Hu, Min Zhang, Siyu Ma, Fanglin Yu, Shiqing.
Products > IRR-MRC5 Transfection Reagent (Irradiated Fibroblasts)
Products > NCI-H441 Transfection Reagent (Lung Adenocarcinoma)
Products > IMR-90 Transfection Reagent (Lung IMR-90, CCL186)
Zihua Zeng, Ching-Hsuan Tung, Youli Zu 
Products > ZR-75-1 Transfection Reagent (Breast Carcinoma, CRL1500)
Human DMBT1-Derived Cell-Penetrating Peptides for Intracellular siRNA Delivery  Martina Tuttolomondo, Cinzia Casella, Pernille Lund Hansen, Ester Polo,
Received 24th March 2010, Accepted 14th July 2010
Molecular Therapy - Nucleic Acids
Molecular Therapy - Nucleic Acids
Products > LNCAP Transfection Reagent (Prostate Carcinoma)
Volume 24, Issue 7, Pages (July 2016)
Products > NCI-H23 Transfection Reagent (Lung Adenocarcinoma)
Particle Tracking Analysis for the Intracellular Trafficking of Nanoparticles Modified with African Swine Fever Virus Protein p54-derived Peptide  Hidetaka.
Volume 14, Issue 3, Pages (September 2006)
Altogen labs Leading Developer and Manufacturer of In Vivo and DNA Transfection Kits, Transfection Reagents and Electroporation Delivery Products Products.
Thermoresponsive Bacteriophage Nanocarrier as a Gene Delivery Vector Targeted to the Gastrointestinal Tract  Katawut Namdee, Mattaka Khongkow, Suwimon.
Ken Ishikawa, Scott H. Medina, Joel P. Schneider, Amar J.S. Klar 
Products > Transfection Reagent for Chromaffin Cells
Altogen labs Leading Developer and Manufacturer of In Vivo and DNA Transfection Kits, Transfection Reagents and Electroporation Delivery Products Products.
Volume 25, Issue 7, Pages (July 2017)
Molecular Therapy - Nucleic Acids
Altogen labs Leading Developer and Manufacturer of In Vivo and DNA Transfection Kits, Transfection Reagents and Electroporation Delivery Products Products.
Anisha Gupta, Elias Quijano, Yanfeng Liu, Raman Bahal, Susan E
Molecular Therapy - Nucleic Acids
Particle assembly incorporating a VP22–BH3 fusion protein, facilitating intracellular delivery, regulated release, and apoptosis  N.D. Brewis, A. Phelan,
Molecular Therapy - Nucleic Acids
2016 Enhanced Synthesis and Purification of PEGylated Liposomes for Targeted Drug Delivery Neil Parikh, Steven Roberts, and Nitin Agrawal
Presentation transcript:

Highlights: Co-delivery of drugs-minicircle DNA by nanoparticle-in-microsphere multipart systems Gas-generating TPGS-PLGA microspheres present a pH-responsive drug release. This study focus on drug-DNA combinatorial therapy to target multiple cancer hallmarks They design the carrier a stimuli-responsive character, specifically for cancer microenvironment

Objectives and rationales Few materials exhibited suitable physicochemical properties to co-delivery small molecule gene combination Peptide-functionalized DSPE/PEG liposome: paclitazel and miRNA antagomir 10b Triblock copolymer micelle: Dox and mcDNA design: must display hydrophilic or hydrophobic character for drug encapsulation and positively charged groups for DNA condensation (peptide: histidine rich-protonate into positive charge in acidic environment) Amphiphilic (CDI:carbonyldiimidazole-) V.M. Gaspar, C. Gonçalves, D. de Melo-Diogo, E.C. Costa, J.A. Queiroz, C. Pichon, F. Sousa, I.J. Correia, Journal of Controlled Release 189 (2014) 90-104. Q. Zhang, R. Ran, L. Zhang, Y. Liu, L. Mei, Z. Zhang, H. Gao, Q. He, Journal of Controlled Release 197 (2015) 208-218.

Objectives and rationales Manipulating drug or gene release in a spatially and temporally controlled at the target site: Gas-generating pH-sensitive carrier: mediated by bicarbonate salts (NaHCO3 or NH4HCO3) Cholesterol-mPEG2000-DSPE liposome loading NH4HCO3 and Dox: delivered to multi-drug resistant breast cancer Develop a nanoparticle in microsphere hybrid delivery system (NIMPS): Amino acid-modified (L-histidine and L-arginine) chitosan nanoparticle: mcDNA (3.06kbp) Doxorubin TPGS coating: D-α-tocopherol PEG succinate, enhance cellular uptake and particle stability Gas triggering release has been demonstrated and showed increased intracellular drug conc. Bacterial plasmid DNA is a common choice. (include a bacterial origin of replication and an antibiotic resistance gene, transcription unit: promotor and polyA, replicate independently from host DNA)

McDNA An inherent supercoiled topological isoform The lack of any bac-ORI The absence of any sequence coding for antibiotic resistance The existence of a therapeutic transgene whose expression is controlled by a mammalian promoter The existence of a specific sequence attributed to the site of recombination where the precursor parental plasmid (PP) yields the minicircle Minimalistic backbone (exclude bac-ORI, no antibiotic resistance, controlled by mammalian promoter) Avoid any possible horizontal gene transfer, mcDNA size is smaller (2.9kbp) and 77 fold high expression compared to 52kbp Expert opinion on biological therapy 15(3) (2015) 353-379.

DOX-loaded gas-generating hollow microspheres Double emulsion solvent diffusion-evaporation method: W/O/W +hydrophobic DOX (convert Doxorubicin hydrochloride salt by adding TEA prior to formulation) +CH-HR-mcDNA The NaHCO3+DOX were initially added to PVA solution and stirred. Then PLGA in DCM (O) were dropped into aqueous phase=>sonicated=> primary emulsification Then PVA or TPGS as surfactant were added to primary W/O emulsion=>homogenized=> then transfer to DI water and let organic solvent evaporated.

mcDNA amino acid-Chitosan nanoparticles EDC/NHS coupling: primary amine group (in chitosan glucosamine) and carboxylic acid (histidine, arginine) Complex DNA with chitosan nanoparticle by incubation for 30 min V. Gaspar, J. Marques, F. Sousa, R. Louro, J. Queiroz, I. Correia, Nanotechnology 24(27) (2013) 275101.

Formulation of gas-generating PLGA microspheres PLGA microsphere-PVA PLGA microsphere-TPGS TPGS: low Polydispersity than PVA=> more homogeneous TGPS: larger size, PEG shell TGPS: slightly decrease of zeta-potential In accordance with previous literature

Formulation of gas-generating PLGA microspheres Determined through UV-vis spectrophotometry at λ=485nm X-ray diffraction X-ray: No significant difference between microPVA and TGPS Encapsulation efficiency: >95% (previously article use liquid chromatography: crizotinib, sildenafil)

Formulation of gas-generating PLGA microspheres micro-PVA-DOX micro-TGPS-DOX After loading drug, maintain spherical shape After loading drug: lead to smaller particle (1877nm compared to 2362nm) Charge changed closed to neutral (-9.7) (compared to -21), affect therapeutic efficiency: previously demonstrated that particle zeta potential in the range of neutrality (+10~-10) achieve optimal for tumor penetration.

Microcarriers biological characterization- in vitro biocompatibility Evaluated by resazurin assay. HeLa cell Positive control: HeLa cell in ethanol Blank micro-PVA Like alamarBlue assay, cell permeable redox indicator, viable cells with active metabolism can reduce resazurin into the resorufin product which is pink and fluorescent, slightly more sensitive than tetrazolium reduction (MTS). “usually measure fluorescence”, can be multiplexed with other methods such as measuring caspase activity to study the mechanism of cytotoxicity. 98% of viability. Blank micro-TGPS

Microcarriers biological characterization- Cellular uptake Flow cytometry and confocal microscope Cells: stained with WGA-Alexa Fluor594 (cell surface glycoprotein) Micro TPGS exhibits effective cell uptake

Cellular uptake Micro-TGPS shows 5.2 fold higher than micro-PVA % positive cells: 5.2 fold higher cellular uptake in comparison to micro PVA, in agreement with previous literature. Free drug particularly accumulated in the nuclear compartment, while micro PVA shows a widespread distribution (previous page). TPGS showed a clear accumulation of drug in nuclear compartment. (Therapeutic efficacy: Dox located in nuclear to inhibits the progression of topoisomerase. II PLGA-PVA: energy independent, macropynocytosis internalization

Stimuli-responsive drug release In acid medium: a rapid and extensive Dox release 3.88 fold higher drug release at 8hr Negligible burst release at pH7.4. Only 13% of loaded drug is released at 30h. Retention of the drug: reduces off-target cytotoxicity effects upon their administration Confirm the stimuli-responsive profile.

Stimuli-responsive drug release PLGA-microTPGS: preserve morphology integrity at pH7.4. Confirm the stimuli-responsive profile.

Formulation of drug-gene loaded pH-responsive PLGA Microspheres (NIMPS) mcDNA chitosan nanoparticles: assembled via electrostatic attraction (incubation) Characterization of mcDNA chitosan nanoparticles: DLS: 180nm Agarose electrophoresis: lane1-free mcDNA, lane2-CH-HR-mcDNA Zeta-potential: positive charge 1. Chitosan np can completely condense mcDNA

Formulation of drug-gene loaded pH-responsive PLGA Microspheres (NIMPS) mcDNA: FITC labelled Dual loaded showed less negative zeta potential compared to single loaded SEM show NIMPS maintain their spherical morphology B=3D reconstruction

Formulation of drug-gene loaded pH-responsive PLGA Microspheres (NIMPS) CH-HR nanoparticles inclusion in micro-TPGS-Dox microcarriers Co-localization of Dox and nanocarrier (FITC-mcDNA) Colocalization analysis was performed by using thresholded mander’s colocalization algorithm (tM: 0.9264).

NIMPS cellular uptake and gene expression Flow cytometry: hybrid NIMPS demonstrated higher internalization (87.1%) in comparison to micro-TPGS-Dox (72.9%) NIMPS are localized in the intracellular compartment and that Dox is present in cell nucleus.

NIMPS cellular uptake and gene expression GFP of CH-HR-mcDNA is slightly higher than NIMPS-mcDNA. quantified by confocal microscopy quantified by spectrofluorimetry Maybe attributed to that mcDNA NP must be released from microocarriers before being localized.

Delivery systems cytotoxic activity MTS assay Micro-TPGS-Dox displays 1.7 fold higher cytotoxicity than Micro-PVA-Dox NIMPS-Dox-mcDNA causes significant higher cytotoxicity.

Conclusions Inclusion of TPGS as coating for PLGA improved cellular uptake. Minicircle DNA nanoparticles inside microspheres promote transgene expression. Lack of the release profile and carrier stability for co-delivery formulation. Drug-gene loaded systems present higher cytotoxic activity in cancer cells. They did not report the effective dosage

References Q. Zhang, R. Ran, L. Zhang, Y. Liu, L. Mei, Z. Zhang, H. Gao, Q. He, Simultaneous delivery of therapeutic antagomirs with paclitaxel for the management of metastatic tumors by a pH-responsive anti-microbial peptide-mediated liposomal delivery system, Journal of Controlled Release 197 (2015) 208-218. V.M. Gaspar, C. Gonçalves, D. de Melo-Diogo, E.C. Costa, J.A. Queiroz, C. Pichon, F. Sousa, I.J. Correia, Poly (2-ethyl-2-oxazoline)–PLA-g–PEI amphiphilic triblock micelles for co-delivery of minicircle DNA and chemotherapeutics, Journal of Controlled Release 189 (2014) 90-104. V. Gaspar, D.d. Melo-Diogo, E. Costa, A. Moreira, J. Queiroz, C. Pichon, I. Correia, F. Sousa, Minicircle DNA vectors for gene therapy: advances and applications, Expert opinion on biological therapy 15(3) (2015) 353-379. V. Gaspar, J. Marques, F. Sousa, R. Louro, J. Queiroz, I. Correia, Biofunctionalized nanoparticles with pH-responsive and cell penetrating blocks for gene delivery, Nanotechnology 24(27) (2013) 275101.